374 related articles for article (PubMed ID: 27626176)
21. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights.
Shokoohian B; Negahdari B; Aboulkheyr Es H; Abedi-Valugerdi M; Baghaei K; Agarwal T; Maiti TK; Hassan M; Najimi M; Vosough M
J Cell Mol Med; 2021 Sep; 25(18):8602-8614. PubMed ID: 34423899
[TBL] [Abstract][Full Text] [Related]
22. Palliative treatment in advanced hepatocellular carcinoma: has it made any difference?
Paul SB; Manjunatha YC; Acharya SK
Trop Gastroenterol; 2009; 30(3):125-34. PubMed ID: 20306740
[TBL] [Abstract][Full Text] [Related]
23. Evolution of systemic treatment for advanced hepatocellular carcinoma.
Wu TC; Shen YC; Cheng AL
Kaohsiung J Med Sci; 2021 Aug; 37(8):643-653. PubMed ID: 34213069
[TBL] [Abstract][Full Text] [Related]
24. Potentiality of immunotherapy against hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
[TBL] [Abstract][Full Text] [Related]
25. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
Ruan Q; Wang H; Burke LJ; Bridle KR; Li X; Zhao CX; Crawford DHG; Roberts MS; Liang X
Int J Cancer; 2020 Sep; 147(6):1519-1527. PubMed ID: 32010970
[TBL] [Abstract][Full Text] [Related]
27. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic options in hepatocellular carcinoma: a comprehensive review.
Suresh D; Srinivas AN; Prashant A; Harikumar KB; Kumar DP
Clin Exp Med; 2023 Oct; 23(6):1901-1916. PubMed ID: 36780119
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Liver Cancer.
Liu CY; Chen KF; Chen PJ
Cold Spring Harb Perspect Med; 2015 Jul; 5(9):a021535. PubMed ID: 26187874
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
31. Advanced Hepatocellular Cancer: the Current State of Future Research.
Connell LC; Harding JJ; Abou-Alfa GK
Curr Treat Options Oncol; 2016 Aug; 17(8):43. PubMed ID: 27344158
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
Wang Z; Zhang G; Wu J; Jia M
Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
[TBL] [Abstract][Full Text] [Related]
33. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
34. [Hepatocellular Carcinoma: therapeutic options 2015].
Schultheiß M; Bettinger D; Neeff HP; Brunner TB; Thimme R
Dtsch Med Wochenschr; 2015 Jul; 140(14):1063-8. PubMed ID: 26182255
[TBL] [Abstract][Full Text] [Related]
35. Challenges in liver cancer and possible treatment approaches.
Anwanwan D; Singh SK; Singh S; Saikam V; Singh R
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188314. PubMed ID: 31682895
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapies in hepatocellular carcinoma: present and future.
Bertino G; Di Carlo I; Ardiri A; Calvagno GS; Demma S; Malaguarnera G; Bertino N; Malaguarnera M; Toro A; Malaguarnera M
Future Oncol; 2013 Oct; 9(10):1533-48. PubMed ID: 24106903
[TBL] [Abstract][Full Text] [Related]
37. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
Sun JY; Yin T; Zhang XY; Lu XJ
J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
[TBL] [Abstract][Full Text] [Related]
39. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
40. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.
Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X
J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
